tbuckley/cabot-search huggingface dataset:
The Florence Statement on Triclosan and Triclocarban
Authors: Rolf U. Halden, Avery E. Lindeman, Allison E. Aiello, David Andrews, William A. Arnold, Patricia Fair, Rebecca E. Fuoco, Laura A. Geer, Paula I. Johnson, Rainer Lohmann, Kristopher McNeill, Victoria P. Sacks, Ted Schettler, Roland Weber, R. Thomas Zoeller, Arlene Blum
Journal: Environmental Health Perspectives (2017)

The Florence Statement on Triclosan and Triclocarban documents a consensus of more than 200 scientists and medical professionals on the hazards of and lack of demonstrated benefit from common uses of triclosan and triclocarban. These chemicals may be used in thousands of personal care and consumer products as well as in building materials. Based on extensive peer-reviewed research, this statement concludes that triclosan and triclocarban are environmentally persistent endocrine disruptors that bioaccumulate in and are toxic to aquatic and other organisms. Evidence of other hazards to humans and ecosystems from triclosan and triclocarban is presented along with recommendations intended to prevent future harm from triclosan, triclocarban, and antimicrobial substances with similar properties and effects. Because antimicrobials can have unintended adverse health and environmental impacts, they should only be used when they provide an evidence-based health benefit. Greater transparency is needed in product formulations, and before an antimicrobial is incorporated into a product, the long-term health and ecological impacts should be evaluated. https://doi.org/10.1289/EHP1788.
Biocompatible PEGylated bismuth nanocrystals: “All-in-one” theranostic agent with triple-modal imaging and efficient in vivo photothermal ablation of tumors
Authors: Zhenglin Li, Jing Liu, Ying Hu, Zhuo Li, Xuelei Fan, Ye Sun, Flemming Besenbacher, Chunying Chen, Miao Yu
Journal: Biomaterials (2017)
A Phase Ib/II Study of Cancer Stemness Inhibitor Napabucasin (BB608) Combined with Weekly Paclitaxel in Advanced Triple Negative Breast Cancer.
Authors: Carlos Becerra, Fadi S. Braiteh, Alexander I. Spira, Adrian Langleben, Lawrence C. Panasci, Svetislava J. Vukelja, Ioana M. Hinshaw, Rachel Anne Goodwin, Timothy J. Panella, William Jeffery Edenfield, Kimiko Kossler, Stephanie Hume, Youzhi Li, Matthew Hitron, Chiang Li
Journal: Journal of Clinical Oncology (2016)

1094 Background: Napabucasin (BBI-608, BB608) is a first-in-class cancer stemness inhibitor that targets the STAT3 pathway that has shown potent synergistic preclinical anti-tumor activity with paclitaxel. In a phase Ib dose escalation study in patients (pts) with advanced solid tumors, BB608 plus weekly paclitaxel was well tolerated. Methods: Pts with metastatic triple negative breast cancer (TNBC) who progressed on prior systemic therapy (including prior taxanes) were enrolled to assess safety, tolerability, and preliminary anti-cancer activity. BB608 was administered orally at 480 mg twice daily with paclitaxel 80 mg/m2 IV weekly 3 of every 4 weeks. A sample size of 40 set the bounds of the 90% CI at ±10% to 14%, assuming a disease control rate (DCR) of 60% to 80%. Disease control is defined as stable disease (SD) for at least 8 weeks, or objective partial (PR) or complete response (CR) per RECIST 1.1. Results: 35 pts enrolled, having received a median of 4 prior lines of therapy, including 33 pts (94%) that had progressed on prior taxane-based regimens. Treatment was tolerated without dose-limiting toxicity or unexpected adverse events (AE). Related grade 3 AE were rapidly reversible and included diarrhea (n = 3), as well as nausea, vomiting, anorexia, abdominal pain, and fatigue (n = 1 each). For evaluable pts (n = 31), DCR is 55% and ORR is 13%. For the intent to treat population (n = 35), mPFS is 10.6 weeks and mOS is 37 weeks. Conclusions: BB608 plus weekly paclitaxel has demonstrated safety, tolerability, and promising signs of anti-cancer activity in pts with heavily pretreated TNBC who have progressed following treatment with taxane-based regimens. Clinical trial information: NCT01325441.
A multicenter phase I/II study of TAS-102 with nintedanib in patients (pts) with metastatic colorectal cancer (mCRC) refractory to standard therapies (N-TASK FORCE): EPOC1410.
Authors: Yasutoshi Kuboki, Tomohiro Nishina, Kensei Yamaguchi, Eiji Shinozaki, Yoshito Komatsu, Satoshi Yuki, Kentaro Yamazaki, Hiroki Hara, Miki Fukutani, Yasue Uchida, Natsuko Tsukahara, Hiromi Hasegawa, Seiko Matsuda, Wataru Okamoto, Masahito Yonemura, Shogo Nomura, Akihiro Sato, Atsushi Ohtsu, Takayuki Yoshino
Journal: Journal of Clinical Oncology (2016)

TPS3632 Background: In a RECOURSE phase III study, TAS-102 significantly improved progression-free survival (PFS) and overall survival (OS) over placebo in patients (pts) with metastatic colorectal cancer (mCRC) refractory to standard therapies. We reported the combination of TAS-102 with bevacizumab (C-TASK FORCE trial) showed promising anti-tumor activities with mild toxicities (Kuboki Y, et al. ASCO 2015). Nintedanib is a triple angiokinase inhibitor of vascular endothelial growth factor receptors (1,2,3), platelet-derived growth factor receptors (a, β), and fibroblast growth factor receptors (1,2,3). A global phase III study, called as the LUME-Colon 1, comparing nintedanib monotherapy versus placebo in pts with mCRC refractory to standard therapies is ongoing, on the basis of promising anti-tumor activities with mild toxicities in a phase I clinical study of nintedanib monotherapy (Mross et al.). Therefore, we initiated phase I/II study to assess efficacy and safety for the combination of TAS-102 with nintedanib. Methods: The key eligibility criteria were pts with mCRC refractory or intolerant to fluoropyrimidine, irinotecan, oxaliplatin, anti-angiogenesis inhibitor and anti-EGFR antibody (if wild-type RAS) and without prior regorafenib and TAS-102; at least one measurable lesion; and ECOG performance status of 0 or 1. Phase I part was designed to determine the recommended phase II dose (RP2D) in a “3+3” cohort-based dose escalation design of nintedanib (150mg BID every day on level 1 and 200mg BID every day on level 2) with a fixed dose of TAS-102 (35 mg/m2 BID on days 1–5 and 8–12 q4w). Primary endpoint of the phase II part was an investigator-assessed PFS rate at 16 weeks in pts receiving the combination with RP2D. Using a single stage binomial design, this study required 52 pts, with an investigator-assessed PFS rate at 16 weeks of 40% deemed promising and 25% unacceptable (one-sided alpha = 0.1; beta = 0.2). Secondary endpoints included OS, PFS, objective response rate, disease control rate, safety, and pharmacokinetic parameters. The enrollment to phase II part began in January 2016. Clinical trial information: UMIN000017114. Clinical trial information: 000017114.
Complications of Diabetes Diagnosed in Children and Adolescents
Authors: Shiqiao Peng, Chenyan Li, Xuren Sun
Journal: JAMA (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Construction of an alkaline phosphatase-specific two-photon probe and its imaging application in living cells and tissues
Authors: Huatang Zhang, Peng Xiao, Yin Ting Wong, Wei Shen, Mohit Chhabra, Raoul Peltier, Yin Jiang, Yonghe He, Jun He, Yi Tan, Yusheng Xie, Derek Ho, Yun-Wah Lam, Jinpeng Sun, Hongyan Sun
Journal: Biomaterials (2017)
Areola sparing mastectomy without preservation of nipple: A clinicopathological assessment and a case series.
Authors: Houpu Yang, Shu Wang, Fei Xie, Jiajia Guo, Xiaoyong Chen, Changjiang Yu, Chuan Wang, Zhiqiong Zhang, Xiaoxia Yu
Journal: Journal of Clinical Oncology (2017)

e12099 Background: Preservation of the nipple-areolar complex has gained worldwide popularity due to significantly improved cosmetic result of mastectomy, while 4% to 58% involvement of nipple and assumed increased recurrence risk made it controversial on the oncological safety of nipple sparing mastectomy. This study focuses on the oncological feasibility of areola sparing mastectomy without preservation of nipple by evaluating involvement of the areola and nipple separately in consecutive mastectomy specimens. Methods: During Aug 3, 2016 to Jan 25, 2017, consecutive specimens from women underwent traditional mastectomy were analyzed. Areolae and nipples were resected and sectioned separately. Involvement of nipple and areola and clinicopathological data were analyzed. The results of 4 patients underwent areola sparing mastectomy were studied. Results: The overall frequency of malignant involvement of the areola among the breasts was 3 of 127 (2.3%), which was significantly lower than that of the nipple (11 of 127, 8.7%, p = 0.03). In patients whose tumors were ≤3cm, outside areolar area, and without dimpling of areola or inflammatory appearance, the incidence of areolar involvement was low to zero. A total of 4 patients received areola sparing mastectomy by “nipple coring” and immediate implant based reconstruction. No patients desired nipple reconstruction. Cosmetic results were all good. Conclusions: Areolae were rarely involved in breasts with tumor ≤3cm, and without inflammatory skin, dimpling of areola or retro-areolar tumor. Areola sparing mastectomy might be oncologically safe and should be a potential treatment in selected patients.
Preparing clinicians for (re-)emerging arbovirus infectious diseases in Europe
Authors: L. Sigfrid, C. Reusken, I. Eckerle, V. Nussenblatt, S. Lipworth, J. Messina, M. Kraemer, O. Ergonul, A. Papa, M. Koopmans, P. Horby
Journal: Clinical Microbiology and Infection (2017)
The long non-coding RNA BC200 (BCYRN1) is critical for cancer cell survival and proliferation
Authors: Evan P. Booy, Ewan KS McRae, Amit Koul, Francis Lin, Sean A. McKenna
Journal: Molecular Cancer (2017)

BC200 is a long non-coding RNA expressed at high levels in the brain and elevated in a variety of tumour types. BC200 has a hypothesized role in translational regulation; however, to date the functional role of BC200 in both normal and diseased states remains poorly characterized. Detailed BC200 expression analyses were performed in tumor cell lines, primary and non-tumorigenic cultured breast and lung cells, and a panel of normal human tissues by quantitative real-time PCR and confirmed by northern blot. Subcellular fractionation was performed to assess BC200 distribution and efficient knock-down of BC200 was established using both locked nucleic acid (LNA) GapmeRs and conventional siRNAs. Cell viability following BC200 knockdown and overexpression was assessed by MTT assay and induction of apoptosis was monitored by Annexin V/PI staining and flow cytometry. Cell cycle arrest and synchronization were performed using serum withdrawal as well as the specific inhibitors Lovastatin, Thymidine, RO3306 and Nocodazole. Synchronization was monitored by fluorescent analysis of cellular DNA content by flow cytometry BC200 expression was substantially upregulated in brain and elevated expression was also observed in testes, small intestine and ovary. Expression in cultured tumour cells was dramatically higher than corresponding normal tissue; however, expression in cultured primary cells was similar to that in immortalized and cancer cell lines. BC200 knockdown resulted in a dramatic loss of viability through growth arrest and induction of apoptosis that could be partially rescued by overexpression of wild-type BC200 but not an siRNA-resistant sequence mutant. A substantial decrease in BC200 expression was observed upon cell confluence or serum deprivation, as well as drug induced cell cycle arrest in G1 or G2 but not S- or M-phases. Upon release from cell cycle arrest, BC200 expression was recovered as cells entered S-phase, but did not follow a periodic expression pattern during synchronized progression through the cell cycle. This elevated expression was critical for the survival of proliferating cancerous and non-cancerous cells, but is dispensable upon senescence or cell cycle arrest. BC200 expression is elevated in proliferating cultured cells regardless of origin. In primary cells, expression is dramatically reduced upon cell cycle arrest by confluence, serum deprivation or chemical inhibition. The lethality of BC200 knockdown is restricted to actively proliferating cells, making it a promising therapeutic target for a broad spectrum of cancers.
Assessing the Feasibility of Pathology Informatics Approaches for Subtyping Diffuse Large B-Cell Lymphoma (DLBCL)
Authors: Serina J Lewis, Jordan Goldstein, Monique Farone, Anh Thuy Phan, Jean L. Koff, Ashley D. Staton, Pooya Mobadersany, Lee Cooper, Christopher Flowers
Journal: Blood (2016)
Microanatomie endoscopique de l'oesophage de Barrett avec le système NBI
Authors: K Kuznetsov, JF Rey, R Lambert, C Sattonet
Journal: Endoscopy (2005)

L'objectif de l'endoscopie dans la prévention secondaire de l'adénocarcinome de l'œsophage et de la jonction oesophagogastrique est l'identification des aires de métaplasie intestinale (MI) et de zones planes de néoplasie intraépithéliale. L'endoscopie standard, même avec l'aide d'agents de constraste (bleu de méthylène ou acide acétique), a une efficacité insuffisante pour identifier l'architecture de surface de MI et des zones néoplasiques planes.
Initiation and adherence with bone-targeting agents in US men with bone metastases from prostate cancer.
Authors: Alexander Liede, Anne M. Butler, Karynsa Cetin, Rohini K Hernandez, Robert Overman, JungIn Kim, B. Diane Reams, Bradford Richard Hirsch, Amy Pickar Abernethy, M. Alan Brookhart
Journal: Journal of Clinical Oncology (2016)

e13083 Background: Bone metastases (BM) are common in advanced prostate cancer patients and can lead to serious skeletal-related events (eg, pathological fracture). Two bone-targeting agents (BTAs) are approved in the US for prevention of skeletal-related events in men with BM from prostate cancer – denosumab and zoledronic acid. We sought to provide a current and comprehensive description of BTA use in this population. Methods: Using structured and unstructured data (processed via technology-enabled abstraction) from a large, longitudinal electronic health record database of patients receiving care at oncology practices across the US (Flatiron Health), we identified adult prostate cancer patients with a confirmed diagnosis of BM in 2012/2013 and no evidence of BTA use in the 6 months prior to diagnosis. Patients were followed through 04/30/2015. We estimated the cumulative incidence of BTA initiation after BM diagnosis, treating death as a competing event. Among BTA users, we used multivariable repeated measures generalized linear models to examine demographic/clinical factors associated with non-adherence (defined as absence of treatment in a 30-day interval to closely reflect the labels). Results: Of 897 men in the cohort, mean age at BM was 71 years, 22% also had non-bone metastases, and 8% experienced a prior skeletal-related event. During 1150 person-months of follow-up, 706 patients initiated a BTA and 77 patients died prior to initiation. The cumulative incidence of BTA initiation after BM diagnosis was 24% (95% confidence interval [CI] 21-26%) at 30 days, 76% (95% CI 68-84%) at 180 days, and 89% (95% CI 74-100%) at 1 year. Adherence at 6, 12, and 24 months after initiation was 86% (95% CI 83-88%), 73% (95% CI 70-76%), and 32% (95% CI 28-35%), respectively. We observed an increased risk of non-adherence in men who initiated treatment shortly after a diagnosis of BM (treatment initiated < 3 vs. ≥ 3 months after BM diagnosis). Conclusions: This study of real-world treatment patterns in a population of prostate cancer patients with BM treated in oncology clinics in the US found that most men initiated a BTA > 30 days after BM diagnosis. Adherence to BTAs decreased over time, with a substantial decline after 12 months.
Effect of Tolbutamide on Weight Gain, Blood Sugar, and Serum Proteins in Geriatric Patients
Authors: H L SCHIPPER
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Caspase modelling to predict personalised risk in stage III colorectal cancer (CRC) patients.
Authors: Manuela Salvucci, Maximilian Wuerstle, Mattia Cremona, Sarah Curry, Clare Morgan, Andreas Ulrich Lindner, Orna Bacon, Alexa Resler, Aine Murphy, Daniel Longley, Richard H. Wilson, Sophie Camilleri-Broët, Manuel Salto-Tellez, Deborah A McNamara, Elaine Kay, Bryan Hennessy, Pierre Laurent-Puig, Sandra Van Schaeybroeck, Markus Rehm, Jochen Prehn
Journal: Journal of Clinical Oncology (2016)

11592 Background: Aberrant apoptosis is coupled with chemotherapy-resistance. Here, we applied a mathematical model of downstream apoptosis execution (APOPTO-CELL) and investigated its suitability as a prognostic tool in stage III CRC patients. Methods: Patient-specific apoptosis susceptibility (AS) was simulated by APOPTO-CELL from the protein expressions of procaspase-3 (PC3), procaspase-9, SMAC and XIAP quantified by reverse phase protein array on FFPE primary tumour tissue from a prospective multi-centre cohort of n = 120 CRC patients treated with 5-fluorouracil-based chemotherapy. Associations with disease-free survival (DFS) and overall survival (OS) and other clinicopathological features (CPFs) were analysed by Kaplan-Meier estimates, Cox regression models and Random Forest (RF) machine learning. Findings were validated in a colon adenocarcinoma cohort (TCGA COAD, n = 134) where the association of AS with CRC consensus molecular subtypes (CMS) was also explored. Results: Apoptosis-resistant patients were at higher risk of relapse (HR 2.05, 95% CI 1.03–4.05, p = 0.0415) and mortality (HR 3.78, 95% CI 1.42–10.08, p = 0.0057). Factoring in PC3 apoptosome-independent impact by combining PC3 with AS (PC3 + AS) led to an improved prognostic marker (+8.5% and +9.0% in Harrell's concordance index for DFS and OS, respectively) independent of other CPFs. PC3 + AS was identified as the major predictor in a RF relapse classifier (RFRC). The prognostic signatures were independently validated in stage III TCGA COAD patients (n = 41; DFS logrank p = 0.0130 (AS), p = 0.0415 (PC3 + AS) and p = 0.0401 (RFRC)). Association between reduced AS and increased relapse risk (HR 2.99, 95% CI 1.17–7.62, p = 0.0217) was limited to CMS1-3 (interaction p = 0.0061). Likelihood of response and ad hoc dosage for targeted therapeutics (SMAC-mimetics family) was determined in silico for high risk patients. Conclusions: Apoptosis modelling links primary tumours molecular traits to an individualised likelihood of response to chemotherapeutics that i) complements clinicopathological features, ii) identify optimal targeted therapeutic regime in high risk patients and provides actionable insights to inform the clinical-decision making process.
Richter's syndrome (RS) in patients with chronic lymphocytic leukemia (CLL) on novel agent therapy.
Authors: Matthew Steven Davids, Ying Huang, Kerry Anne Rogers, Robert Stern, Jennifer R. Brown, Philip A. Thompson, Danielle M. Brander, Alexey Valeryevich Danilov, Chaitra Shankar Ujjani, Sameer Ashok Parikh, Jacqueline Claudia Barrientos, Constantine Tam, Jennifer Ann Woyach
Journal: Journal of Clinical Oncology (2017)

7505 Background: Novel agents (NA) targeting B cell receptor kinases and Bcl-2 have substantially improved outcomes in CLL; however, the development of RS in CLL patients (pts) on NAs has been observed, and has not been systematically evaluated. Methods: We retrospectively reviewed pts at 9 academic centers diagnosed with pathologically-confirmed RS from 2011-16. Informed consent was provided through IRB-approved protocols. Descriptive statistics were utilized and overall survival (OS) was calculated from RS diagnosis (dx) to death or last follow-up by Kaplan-Meier. Results: 71 pts who developed RS on NAs for CLL were identified. Median age at CLL dx was 55 yrs (range 21-82), median of 3 therapies (range 0-12) prior to the NA. 68% pts were fludarabine-refractory, and 5 pts (7%) had relapsed post alloHCT. Median time from CLL dx to initiation of NA was 68.5 mo. (range 1.1-246.2). FISH at NA initiation: del(17p) 30/61 (49%), del(11q) 15/61 (25%), trisomy 12 15/61 (25%). Complex karyotype was present in 40/53 (75%). 46/52 (88%) were IGHV unmutated, VH1-69 10/43 (23%), VH4-39 4/43 (9%). 59 (83%) pts were on a BTK inhibitor, 6 (8%) PI3K inhibitor, 6 (8%) venetoclax. RS histology: DLBCL (87%), plasmablastic (6%), Hodgkin (4%), 3% other. RS Ki-67%: &gt;90 (23%), 75-90 (25%), 50-75% (25%), &lt;50% (28%). Median time from start of NA to RS dx was 9.1 mo (range 0.9-48.2), with 65% developing RS within 12 mo. of starting NA. In 56 pts, 19 different regimens were used as initial RS therapy, including: R-EPOCH (36%), R-CHOP (20%), checkpoint blockade (9%), OFAR (7%), or a different NA (7%). Of the 48 pts evaluable for response, ORR was 42% (15% CR, 27% PR). In 29 evaluable pts receiving R-EPOCH/CHOP, ORR was 48% (21% CR). With a median follow-up of 10.6 mo., median OS was only 3.3 mo. (95%CI 2.2-6.0), though none of the 7 pts who achieved CR has died. Conclusions: We report to our knowledge the largest series of CLL pts developing RS on NAs. Pts often had high risk CLL, particularly complex cytogenetics, and RS frequently developed within the first year of NA therapy. Substantial variation exists in treatment, and outcomes are poor for those who do not achieve CR. Identification of molecular drivers of RS and development of novel treatment strategies are urgently needed.